The PPARδ ligand L-165041 inhibits vegf-induced angiogenesis, but the antiangiogenic effect is not related to PPARδ

Journal of Cellular Biochemistry

Volumn 113, Issue 6, 2012, Pages 1947-1954

  Park, Jin Hee ^a   Lee, Kuy Sook ^a   Lim, Hyun Joung ^a   Kim, Hanna ^a   Kwak, Hyun Jeong ^a   Park, Hyun Young ^a  

^a Korea National Institute of Health   (South Korea)

Author keywords

ANGIOGENESIS; CELL CYCLE; ENDOTHELIAL CELL; PPAR

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN A; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOXYACETATES; PHOSPHORYLATION; PPAR DELTA; RETINOBLASTOMA PROTEIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84859589164     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24063     Document Type: Article

References (44)

1. Al Alem L, Southard RC, Kilgore MW, Curry TE,. 2011. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARgamma independent manner. PLoS ONE 6: e16179. DOI: 10.1371/journal.pone.0016179
2. Andres V,. 2004. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: New perspectives and therapeutic potential. Cardiovasc Res 63: 11-21.
3. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG, Moller DE,. 1999. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 274: 6718-6725.
4. Brown PJ, Smith-Oliver TA, Charifson PS, Tomkinson NC, Fivush AM, Sternbach DD, Wade LE, Orband-Miller L, Parks DJ, Blanchard SG, Kliewer SA, Lehmann JM, Willson TM,. 1997. Identification of peroxisome proliferator- activated receptor ligands from a biased chemical library. Chem Biol 4: 909-918.
5. Brown PJ, Stuart LW, Hurley KP, Lewis MC, Winegar DA, Wilson JG, Wilkison WO, Ittoop OR, Willson TM,. 2001. Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg Med Chem Lett 11: 1225-1227.
6. Bruemmer D, Yin F, Liu J, Berger JP, Sakai T, Blaschke F, Fleck E, Van Herle AJ, Forman BM, Law RE,. 2003. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circ Res 93: e38-e47.
7. Burdick AD, Bility MT, Girroir EE, Billin AN, Willson TM, Gonzalez FJ, Peters JM,. 2007. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPAR beta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. Cell Signal 19: 1163-1171.
8. Carmeliet P,. 2003. Angiogenesis in health and disease. Nat Med 9: 653-660.
9. Desvergne B, Wahli W,. 1999. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 20: 649-688.
10. Fasciano S, Patel RC, Handy I, Patel CV,. 2005. Regulation of vascular smooth muscle proliferation by heparin: Inhibition of cyclin-dependent kinase 2 activity by p27(kip1). J Biol Chem 280: 15682-15689.
11. Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, Bittard H,. 2002. Differential regulatin of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 277: 23534-23543.
12. Ferrara N, Kerbel RS,. 2005. Angiogenesis as a therapeutic target. Nature 438: 967-974.
13. Folkman J,. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
14. Goetze S, Eilers F, Bungenstock A, Kintscher U, Stawowy P, Blaschke F, Graf K, Law RE, Fleck E, Grafe M,. 2002. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 293: 1431-1437.
15. Graham TL, Mookherjee C, Sucking KE, Palmer CN, Patel L,. 2005. The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis 181: 29-37.
16. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN,. 2004. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10: 245-247.
17. Han JK, Lee HS, Yang HM, Hur J, Jun SI, Kim JY, Cho CH, Koh GY, Peters JM, Park KW, Cho HJ, Lee HY, Kang HJ, Oh BH, Park YB, Kim HS,. 2008. Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Circulation 118: 1021-1033.
18. Hu Y, Liu HB, Simpson RW, Dear AE,. 2011. PPARgamma-independent thiazolidinedione-mediated inhibition of NUR77 expression in vascular endothelial cells. J Endocrinol 208: R1-R7.
19. Karamysheva AF,. 2008. Mechanisms of angiogenesis. Biochemistry (Mosc) 73: 751-762.
20. Khoo CP, Micklem K, Watt SM,. 2011. A comparison of methods for quantifying angiogenesis in the Matrigel assay in vitro. Tissue Eng Part C Methods 17: 895-906.
21. Kim DJ, Murray IA, Burns AM, Gonzalez FJ, Perdew GH, Peters JM,. 2005. Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem 280: 9519-9527.
22. Kim DJ, Bility MT, Billin AN, Willson TM, Gonzalez FJ, Peters JM,. 2006. PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ 13: 53-60.
23. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM,. 1994. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91: 7355-7359.
24. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J,. 1996. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271: 20608-20616.
25. Lee KS, Park JH, Lee S, Lim HJ, Jang Y, Park HY,. 2006. Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. Biochem Biophys Res Commun 346: 83-88.
26. Lim HJ, Lee S, Park JH, Lee KS, Choi HE, Chung KS, Lee HH, Park HY,. 2009. PPAR delta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. Atherosclerosis 202: 446-454.
27. Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK,. 2006. Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 26: 1481-1487.
28. Nicosia RF, Nicosia SV, Smith M,. 1994. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 145: 1023-1029.
29. Nie L, Wise M, Peterson D, Meydani M,. 2006. Mechanism by which avenanthramide-c, a polyphenol of oats, blocks cell cycle progression in vascular smooth muscle cells. Free Radic Biol Med 41: 702-708.
30. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D,. 2007. Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 27: 63-69.
31. Pola R, Gaetani E, Flex A, Aprahamian TR, Bosch-Marce M, Losordo DW, Smith RC, Pola P,. 2004. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: A possible role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol 36: 363-370.
32. Rifkin DB, Moscatelli D,. 1989. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 109: 1-6.
33. Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, Junquero D, Colpaert FC, Delhon A,. 2002. PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435: 143-151.
34. Stephen RL, Gustafsson MC, Jarvis M, Tatoud R, Marshall BR, Knight D, Ehrenborg E, Harris AL, Wolf CR, Palmer CN,. 2004. Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res 64: 3162-3170.
35. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN, Yancopoulos GD,. 1998. Increased vascularization in mice overexpressing angiopoietin-1. Science 282: 468-471.
36. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver WR, Sternbach DD,. 2003. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity. Bioorg Med Chem Lett 13: 1517-1521.
37. Takano H, Hasegawa H, Zou Y, Komuro I,. 2004. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des 10: 2779-2786.
38. Wagner KD, Wagner N,. 2010. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther 125: 423-435.
39. Wang N,. 2008. PPAR-delta in vascular pathophysiology. PPAR Res 2008: 164163, 10. DOI: 10.1155/2008/164163
40. Ward JE, Gould H, Harris T, Bonacci JV, Stewart AG,. 2004. PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms. Br J Pharmacol 141: 517-525.
41. Wei GL, Krasinski K, Kearney M, Isner JM, Walsh K, Andres V,. 1997. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res 80: 418-426.
42. Willson TM, Brown PJ, Sternbach DD, Henke BR,. 2000. The PPARs: From orphan receptors to drug discovery. J Med Chem 43: 527-550.
43. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV,. 1999. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3: 397-403.
44. Zhan Y, Kim S, Yasumoto H, Namba M, Miyazaki H, Iwao H,. 2002. Effects of dominant-negative c-Jun on platelet-derived growth factor-induced vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol 22: 82-88.